Index, I think few have grasped the significance of Mason's post.
Fto inhibition significantly decreases HCM viability when dosed with cardiotoxic agents. Zan was just used in combination with a cardiotoxic agent, yet no (NONE!) cardiotoxicity was observed...
Either one of two sceneries have occurred (IMO):
1. Zan doesn't inhibit FTO and the 25% reduction in Clofarabine dosing was sufficient to decrease 27% LV dysfunction cases to 0%.
2. Zan is cardioprotective.
Index, I think few have grasped the significance of Mason's...
-
- There are more pages in this discussion • 378 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.65 |
Change
-0.080(4.64%) |
Mkt cap ! $292.1M | |||
| Open | High | Low | Value | Volume |
| $1.76 | $1.77 | $1.60 | $275.4K | 162.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3950 | $1.64 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.70 | 1424 | 2 |
View Market Depth
| Last trade - 15.05pm 23/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |